...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Chemotherapy-induced Changes and Immunosenescence of CD8(+) T-Cells in Patients with Breast Cancer
【24h】

Chemotherapy-induced Changes and Immunosenescence of CD8(+) T-Cells in Patients with Breast Cancer

机译：化疗引起的乳腺癌患者CD8（+）T细胞的变化和免疫荧光

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Changes in sub-populations of cytotoxic (CD8(+)) T-cells, which are observed in aging and in conditions of chronic immune stimulation, are not well-documented in cancer. Materials and Methods: Using flow cytometry, CD8(+) T-cell subsets were analyzed in patients with breast cancer undergoing DNA-damaging chemotherapy and in an older female control group during a six-month longitudinal study, to explore shifts in CD8(+) T-cells and the effect of DNA-damaging chemotherapy on different T-cell sub-populations. Results: As expected, there was a consistent decrease in absolute numbers of leukocytes, lymphocytes, T-cells and CD8(+) T-cells during chemotherapy in patients with cancer. Among the T-cells, there was a lower CD8(-)/CD8(+) ratio, persisting over the six months, in patients with cancer compared to controls. The proportion of CD28(-)CD57(+) cells also remained higher among patients with cancer throughout the sampling duration. The number of CD28(+)CD57(-) and CD28(-)CD5(-) cells decreased faster during DNA-damaging chemotherapy than CD28(+)CD57(+) and CD28(-)CD57(+) cells, while only CD28(-)CD57(-) cells showed a significant reconstitutive capacity after six months. Conclusion: Immunosenescence appeared to be pronounced in patients with breast cancer, with senescent CD8(+) T-cells playing a role. The normal condition was not restored after six months of chemotherapy.
机译：背景：在衰老和慢性免疫刺激条件下观察到的细胞毒性（CD8（+））T细胞亚群的变化在癌症中并未得到充分记录。材料和方法：使用流式细胞仪，在六个月的纵向研究中，对接受DNA破坏性化疗的乳腺癌患者和年龄较大的女性对照组的CD8（+）T细胞亚群进行了分析，以探讨CD8（+）的变化T细胞和DNA损伤化疗对不同T细胞亚群的影响。结果：正如预期的那样，癌症患者化疗期间白细胞，淋巴细胞，T细胞和CD8（+）T细胞的绝对数量持续减少。与对照组相比，癌症患者的T细胞中CD8（-）/ CD8（+）比率较低，并持续了六个月。在整个采样期间，癌症患者中CD28（-）CD57（+）细胞的比例也仍然较高。在DNA损伤化疗期间，CD28（+）CD57（-）和CD28（-）CD5（-）细胞的减少速度比CD28（+）CD57（+）和CD28（-）CD57（+）细胞快，而仅六个月后，CD28（-）CD57（-）细胞显示出显着的重构能力。结论：在乳腺癌患者中免疫衰老似乎很明显，衰老的CD8（+）T细胞发挥了作用。化疗六个月后未恢复正常状态。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号